In 2018, the commonly used targeting drugs for gastric cancer are generally divided into two types, one is anti angiogenesis targeting drugs, and the other is monoclonal antibodies. The target drugs for anti angiogenesis are represented by apatinib, and trastuzumab is represented by monoclonal antibodies. For apatinib, the first indication is gastric cancer. Another drug that can be used is arotinib, which can also be used for the treatment of gastric cancer. For trastuzumab, a comprehensive analysis should be carried out in combination with pathology and immunohistochemistry. It shows that HER2 is positive, which can be added to the FISH test of HER2 gene. If confirmed, trastuzumab can be used for treatment. It is suggested that patients should not use drugs blindly on their own in combination with the opinions of the attending physician.